Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Scribe Therapeutics Inc. (the “Company”) on Form 10-Q for the three months ending June 30, 2026, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Benjamin L. Oakes, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: September 2, 2026

By:

/s/ Benjamin L. Oakes

 

 

Benjamin L. Oakes

 

 

Chief Executive Officer

(Principal Executive Officer)